Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

"This was the largest nationwide population-based longitudinal cohort study to investigate the association between the use of ...

Like other drugs for heart failure, SGLT2 inhibitors were originally developed to lower blood sugar levels in patients with diabetes. But this drug soon found its way into the heart of clinics that ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors — a class of drugs used to treat type 2 diabetes — could also prevent dementia, according to a study published Wednesday in The BMJ.

Taking SGLT-2 inhibitors was associated with a 35% lower risk of developing dementia compared with taking another common diabetes drug with a different mechanism. Although the authors call for ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. New research ...

namely SGLT2-inhibitors and glucagon-like peptide-1 receptor agonists. “As in the current study, the risk of developing ...

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...

Diabetes drugs that cost £1 a day and are already available on the NHS could prevent the onset of dementia, a BMJ study has ...

The researchers found that during a median follow-up of 4.4 years, the primary outcome event of presumed clinical onset of dementia occurred in 69 and 43 participants in the SGLT2 and dulaglutide ...

MoA International Fund earns a High Process Pillar rating. The main driver of the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the firm's average 10-year ...